Peptide science moved from insulin isolation in 1921 to triple agonists in the 2020s. The milestones — and why a research-materials market grew around them.
| Year | Event | Significance |
|---|---|---|
| 1921 | Insulin isolated (Banting, Best) | First peptide therapy |
| 1953 | Insulin structure (Sanger) | Peptide sequencing |
| 1963 | Solid-phase synthesis (Merrifield) | Mass synthesis of any sequence |
| 1970-80s | Somatostatin, LHRH, Soviet nootropics | Neuropeptide discovery boom |
| 1990s | BPC-157 (Zagreb), leptin | Regeneration and signaling |
| 2005+ | GLP-1 therapy (exenatide) | Incretin axis in clinics |
| 2017+ | Semaglutide | Long half-life, weekly dosing |
| 2022+ | Tirzepatide, retatrutide | Multi-agonists |
Three waves: incretins (GLP-1 class), mitochondrial biology (NAD+, MOTS-c, SS-31) and tissue regeneration (BPC-157, TB-500, GHK-Cu).
Related: Russian version · encyclopedia.
Insulin — 1921, the first peptide therapy in history.
1963 — the Merrifield method (Nobel Prize 1984).